Back to top

Analyst Blog

Leading provider of heart support technologies, ABIOMED, Inc. (ABMD - Analyst Report) secured the CE Mark approval to market its Impella RP (Right Peripheral) heart pump in the European Union. Shares of ABIOMED climbed 2.8% following the announcement last week, to close at $24.48 till the last closing date.

ABIOMED’s Impella RP is a percutaneous heart pump that can be planted into the heart via the femoral artery in the thigh without the need for a surgical procedure. It is designed to access the heart’s right ventricle via the vena cava to provide temporary ventricular support for patients with right ventricular failure.

The device delivers over 4 liters of blood per minute from the lower right atrium to the pulmonary artery. As a result, the Impella RP enables surgeons to treat right ventricular dysfunction in a minimally invasive manner.

Impella RP is the latest in ABIOMED’s line of Impella heart pumps. Impella 2.5, Impella 5.0, Impella CP and Impella LD have already secured the U.S. Food and Drug Administration (FDA) pre-market approval. The Impella RP, however, is not currently cleared for sale or use in the U.S.

Last month, ABIOMED had announced successful completion of patient enrolment in the Recover Right clinical trial of its Impella RP in the U.S. The company plans to use the results from the trial to apply for a Humanitarian Device Exemption (HDE) approval, for which it has already received a Humanitarian Use Device (HUD) approval in Jul 2012.

Following the commercial European availability of the new Impella RP device, ABIOMED anticipates the FDA go-ahead by Feb 2015. The company plans to introduce this novel product into its established hospital installed base.

ABIOMED is witnessing strong demand for its Impella line of products as an increasing number of patients are being treated with these devices. Impella utilization thus continues to grow at an impressive pace, with the last reported quarter posting double-digit rise in Impella revenues.

ABIOMED presently carries a Zacks Rank #3 (Hold). Some better-ranked stocks worth a look in the medical instruments industry are Syneron Medical Ltd. (ELOS - Snapshot Report), Delcath Systems, Inc. and Accuray Inc. (ARAY - Analyst Report). While Syneron Medical and Delcath Systems sport a Zacks Rank #1 (Strong Buy), Accuray retains a Zacks Rank #2 (Buy).

Read the Full Research Report on ABMD
Read the Full Research Report on ARAY
Read the Full Research Report on ELOS
Read the Full Research Report on DCTH

Zacks Investment Research

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
SIGNET JEWE… SIG 116.37 +7.72%
CHYRONHEGO… CHYR 2.72 +5.84%
US SILICA H… SLCA 70.72 +4.00%
MALLINCKROD… MNK 80.11 +2.32%
RF MICRO DE… RFMD 11.76 +2.31%